{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:26:24Z","timestamp":1783031184191,"version":"3.54.6"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Patients with nasal metastases are seldom seen among clear cell renal cell carcinoma (CCRCC). We report a rare case presenting as a solitary nasal cutaneous nodule, and summarize the therapeutic experience of tyrosine kinase inhibitors (TKIs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 86-year-old man with a chief complaint of continuous back pain for 3 months and discovery of a cutaneous nodule on the nose for a month visited the oncology department of our hospital. Maxillofacial computed tomography (CT) scans demonstrated a 1.5\u200a\u00d7\u200a0.9\u200acm and ovoid soft tissue density shade at dorsum of the nose. CT of abdomen revealed a 3.5\u200a\u00d7\u200a2.7\u200acm mass in right kidney and presenting an obvious heterogeneous enhancement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The pathological examination of nasal excision biopsy confirmed the diagnosis of nasal clear cell carcinoma. Immunohistochemical analysis indicated that the nasal metastatic tumor had a renal origin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Sunitinib at a dose of 50\u200amg\/day was administered initially, while the serious cutaneous toxicities, especially hand-foot syndrome, occurred to the patient. Subsequently, axitinib at a dose of 5\u200amg twice daily was accepted as second-line treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The nasal mass shrinked significantly after 8-week treatment of axitinib, and the primary tumor has been stable till now.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Axitinib successfully controlled the nasal cutaneous metastasis with mild adverse reactions, and did not aggravate the cutaneous toxicities resulting from sunitinib. The incidence of cutaneous adverse events were low which had been reported by previous studies; however, it is difficult to say that axitinib is a more effective treatment modality for RCC with nasal metastases, which requires further studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014012","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T07:15:32Z","timestamp":1548400532000},"page":"e14012","source":"Crossref","is-referenced-by-count":8,"title":["Metastases to the nose from clear cell renal cell carcinoma"],"prefix":"10.1097","volume":"98","author":[{"given":"Pengfei","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Cong","sequence":"additional","affiliation":[{"name":"Department of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Hospital of Jilin University, Changchun, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat Genet"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/1752-1947-5-429","article-title":"Atypical presentations and rare metastatic sites of renal cell carcinoma: a review of case reports","volume":"5","author":"Sountoulides","year":"2011","journal-title":"J Med Case Rep"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000111742","article-title":"Cutaneous metastases in renal cell carcinoma","volume":"80","author":"Bujons","year":"2008","journal-title":"Urol Int"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1200\/JCO.2012.45.2003","article-title":"Molecular genetics of clear-cell renal cell carcinoma","volume":"32","author":"James","year":"2014","journal-title":"J Clin Oncol"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/labinvest.2008.65","article-title":"Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells","volume":"88","author":"Kluger","year":"2008","journal-title":"Lab Invest"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1,2,3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2017.04.015","article-title":"Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre","volume":"79","author":"Matias","year":"2017","journal-title":"Eur J Cancer"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clgc.2015.07.001","article-title":"Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma","volume":"13","author":"Rini","year":"2015","journal-title":"Clin Genitourin Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201901250-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:30:48Z","timestamp":1694716248000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201901250-00008"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014012","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}